NeuroPace $102 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
4/26/2021

Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 6,900,000 shares of common stock of NeuroPace, Inc. at $17.00 per share (which includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares), for total gross proceeds of $102 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “NPCE.”

Based in Mountain View, California, NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source.

The Davis Polk corporate team included partners Alan F. Denenberg, counsel Jason Bassetti and associates Alex DeGroat and Elsie Cheang. The intellectual property team included partner David R. Bauer and associate Mikaela Dealissia. The tax team included counsel Kiara L. Rankin and associate Benjamin Helfgott. Counsel Marcie A. Goldstein provided FINRA advice. Associate Allison Gunther provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.